United Therapeutics (UTHR) Metrics: History & Chart

United Therapeutics Corporation(UTHR)

Biotechnology · Silver Spring, MD

$497.11-6.75 (-1.34%)

Delayed quote: Sep 11, 2026, 4:00 PM EDT

About United Therapeutics Corporation

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.

Silver Spring, MD

1,400 employees

www.unither.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Martine A. Rothblatt

View full financials

Third-Party DCF Estimate (FMP)	$755.02
Price Gap vs Third-Party Estimate	+48.97%

7D Total Return	+3.01%
30D Total Return	-4.31%
YTD Total Return	+4.02%
1Y Total Return	+25.51%
3Y Total Return	+124.91%
5Y Total Return	+140.34%
10Y Total Return	+322.49%
15Y Total Return	+1071.76%
20Y Total Return	+1780.06%

2026	+4.02%
2025	+38.09%
2024	+60.46%
2023	-20.93%
2022	+28.70%
2021	+42.35%
2020

CAGR TTM	+25.53%
CAGR 3Y	+31.02%
CAGR 5Y	+19.17%
CAGR 10Y	+15.50%
CAGR 15Y	+17.83%
CAGR 20Y	+15.80%

PE Ratio	18.16
PE Ratio Avg TTM	18.79
PE Ratio Avg 3Y	15.33
Current VS TTM Avg	-3.34%
Current VS 3Y Avg	+18.45%
Current VS 5Y Avg	+13.43%

All Metrics

UTHR Valuation Metrics

UTHR Stock Price Metrics

UTHR Dividend Metrics

UTHR Growth Rate Metrics

UTHR Discounted Cash Flow Metrics

UTHR Returns By Period

UTHR Yearly Returns

UTHR Average Annual Returns By Period (CAGR)

UTHR Revenue Metrics

UTHR PE Ratio Metrics

UTHR PS Ratio Metrics

UTHR PB Ratio Metrics

UTHR Price to Free Cash Flow Ratio Metrics

UTHR Debt to Equity Ratio Metrics

UTHR PEG Ratio Metrics

UTHR FCF Yield

UTHR Earnings Yield

UTHR EBITDA Yield

UTHR OCF Yield

UTHR EV/EBIT Ratio Metrics

UTHR EV/EBITDA Ratio Metrics

UTHR EV/Assets Ratio Metrics

UTHR EV/Sales Ratio Metrics

UTHR Current Ratio Metrics

UTHR Quick Ratio Metrics

UTHR ROIC Metrics

UTHR Return on Assets Metrics

UTHR Return on Equity Metrics

UTHR Net Profit Margin Metrics

UTHR Gross Profit Margin Metrics

UTHR Tax Rate Metrics

PS Ratio	7.36
PS Ratio Avg TTM	7.61
PS Ratio Avg 3Y	6.24
Current VS TTM Avg	-3.30%
Current VS 3Y Avg	+17.92%
Current VS 5Y Avg	+20.84%

PB Ratio	3.63
PB Ratio Avg TTM	3.66
PB Ratio Avg 3Y	2.83
Current VS TTM Avg	-0.95%
Current VS 3Y Avg	+28.44%
Current VS 5Y Avg	+40.56%

PFCF Ratio	21.24
PFCF Ratio Avg TTM	22.47
PFCF Ratio Avg 3Y	18.55
Current VS TTM Avg	-5.48%
Current VS 3Y Avg	+14.53%
Current VS 5Y Avg	+19.70%

Debt/Equity Ratio	0.00
Debt/Equity Ratio Avg TTM	0.00
Debt/Equity Ratio Avg 3Y	0.06
Current VS TTM Avg	-100.00%
Current VS 3Y Avg	-100.00%
Current VS 5Y Avg	-100.00%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	4.71%
FCF Yield Avg TTM	4.52%
FCF Yield Avg 3Y	5.64%
Current VS TTM Avg	+4.24%
Current VS 3Y Avg	-16.50%
Current VS 5Y Avg	-17.67%

Earnings Yield	5.51%
Earnings Yield Avg TTM	5.35%
Earnings Yield Avg 3Y	6.77%
Current VS TTM Avg	+2.91%
Current VS 3Y Avg	-18.65%
Current VS 5Y Avg	-14.61%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	15.26
Ev/Ebit Ratio Avg TTM	15.45
Ev/Ebit Ratio Avg 3Y	12.31
Current VS TTM Avg	-1.25%
Current VS 3Y Avg	+23.95%
Current VS 5Y Avg	+18.90%

Ev/Ebitda Ratio	14.32
Ev/Ebitda Ratio Avg TTM	14.60
Ev/Ebitda Ratio Avg 3Y	11.69
Current VS TTM Avg	-1.93%
Current VS 3Y Avg	+22.49%
Current VS 5Y Avg	+17.45%

Ev/Assets Ratio	2.97
Ev/Assets Ratio Avg TTM	3.09
Ev/Assets Ratio Avg 3Y	2.31
Current VS TTM Avg	-3.91%
Current VS 3Y Avg	+28.83%
Current VS 5Y Avg	+44.93%

Ev/Sales Ratio	6.79
Ev/Sales Ratio Avg TTM	7.19
Ev/Sales Ratio Avg 3Y	5.88
Current VS TTM Avg	-5.56%
Current VS 3Y Avg	+15.51%
Current VS 5Y Avg	+16.18%

Current Ratio	5.73
Current Ratio Avg TTM	6.16
Current Ratio Avg 3Y	5.53
Current VS TTM Avg	-6.91%
Current VS 3Y Avg	+3.57%
Current VS 5Y Avg	-14.48%

Quick Ratio	5.41
Quick Ratio Avg TTM	5.84
Quick Ratio Avg 3Y	5.30
Current VS TTM Avg	-7.31%
Current VS 3Y Avg	+2.16%
Current VS 5Y Avg	-16.00%

ROIC	17.69%
ROIC Avg 3Y	15.12%
ROIC Avg 5Y	14.88%
Current VS 3Y Avg	+16.97%
Current VS 5Y Avg	+18.86%
Current VS 10Y Avg	+19.42%

ROA	18.16%
ROA Avg TTM	16.59%
ROA Avg 3Y	14.73%
Current VS TTM Avg	+9.50%
Current VS 3Y Avg	+23.24%
Current VS 5Y Avg	+37.42%

ROE	20.48%
ROE Avg TTM	19.54%
ROE Avg 3Y	18.39%
Current VS TTM Avg	+4.79%
Current VS 3Y Avg	+11.39%
Current VS 5Y Avg	+22.18%

Net Profit Margin	41.56%
Net Profit Margin Avg TTM	40.98%
Net Profit Margin Avg 3Y	41.12%
Current VS TTM Avg	+1.41%
Current VS 3Y Avg	+1.08%
Current VS 5Y Avg	+2.68%

Gross Profit Margin	86.14%
Gross Pft Margin Avg TTM	86.71%
Gross Pft Margin Avg 3Y	88.51%
Current VS TTM Avg	-0.66%
Current VS 3Y Avg	-2.68%
Current VS 5Y Avg	-4.20%

Tax Rate	10.65%
Tax Rate Avg 3Y	22.83%
Tax Rate Avg 5Y	22.33%
Current VS 3Y Avg	-53.35%
Current VS 5Y Avg	-52.29%
Current VS 10Y Avg	-52.30%